XR Technology Accelerates Smart Lab Solutions in Life Sciences with Nearly RMB 100 Million Raised Within a Year and Files IPO Prospectus

Recently, Shanghai Xrazor Technology Co., Ltd. (“Xrazor Technology”), a company dedicated to providing standardized platforms, products, and solutions for smart laboratories in the life sciences sector, announced the completion of its Pre-A financing round. Led by Yuanhe Origin Capital with participation from Shunwei Capital, the proceeds will be primarily used to accelerate product research and development, mass production, and commercialization.

Previously, Xrazor Technology secured angel-round funding in late 2020 from Zhangke Lingyi Investment. What kind of company is Xrazor Technology, given that it has completed two consecutive financing rounds totaling nearly RMB 100 million within just one year since its establishment? Why does it continue to attract investor favor?

Xrazor Technology, established in late 2020, leverages the core team’s extensive experience in product development and team management within the robotics industry. The company is dedicated to developing standardized products and solutions for the life sciences sector. Its product portfolio spans a wide range of applications, including healthcare, drug discovery, in vitro diagnostics (IVD), biobanking, and genetic engineering, significantly enhancing experimental efficiency and quality.

With the advancement of biotechnology, market demand for biological experiments and testing has surged. Meanwhile, routine experimental procedures still largely rely on manual operations, involving substantial repetitive and mechanized tasks. This has led to high labor costs, low experimental efficiency, and an increased risk of sample contamination.

The urgent need for solutions and the rise of automation technology have further highlighted the value of intelligent, modular products in biological laboratories. Compared with traditional manual operations, automated products for biological laboratories can effectively optimize operational processes, significantly improve work efficiency, reduce errors, and minimize contamination of both the laboratory environment and samples.

At present, there is no shortage of innovators entering the laboratory automation market. However, most existing products suffer from high costs, long design cycles, and operational complexity, which have to some extent hindered the promotion and development of related products.

Xrazor Technology’s products feature modular and standardized designs, enabling the integration of various emerging technologies into robotic arms to achieve rapid, stable, and efficient operations. With compact product and solution structures that save space, they effectively control costs.

Since its inception, Xrazor Technology has successively launched the XR-AUTOLAB, a sample laboratory workstation integrating four major platforms—mobile, execution, visual inspection, and digitalization; the XR-TRANSBOT, a laboratory robot combining mobile and execution platform functionalities; and the XR-LABWARE, a software suite focused on experimental process management monitoring and experimental model design. These solutions are widely applicable to fields such as drug research and development, in vitro diagnostics, and microbiological testing.

In terms of products, Xrazor Technology has independently developed a sterile collaborative robotic arm system and a flexible mobile platform. Leveraging its proprietary core technologies, the products demonstrate excellent kinematic performance, making them well-suited for experimental operations involving materials in various forms, such as fluids, solids, and powders. Furthermore, Xrazor Technology has standardized the hardware and software interfaces of its functional modules, facilitating rapid configuration and zero-downtime task switching.

Xrazor Technology’s ability to rapidly advance product development and commercialization within a short timeframe is clearly underpinned by the support of its professional team.

It is reported that He Xueying, the founder of Xrazor Technology, completed her bachelor’s and master’s degrees in the Department of Automation at Shanghai Jiao Tong University and studied abroad at the University of Michigan. Prior to founding the company, Ms. He served as the Head of the Robotics R&D Center at ABB Group, a global leader in robotics technology, where she accumulated over ten years of experience in managing international teams and products. Other core team members also possess many years of experience in service robot product development and backgrounds in biomedicine, enabling them to effectively identify and translate customer needs into solutions.

Leveraging its products’ superior performance and a deep understanding of customer needs, Xrazor Technology secured orders worth over RMB 10 million within just one year of its establishment, with the majority coming from leading clients in medical institutions, research institutes, biopharmaceuticals, and in vitro diagnostics. First-class product design and project engineering capabilities ensured rapid order fulfillment.

Currently, Xrazor Technology has appointed Li Gang, former President of ABB Robotics China, as its Chief Scientific Advisor. As the company is in a phase of rapid development, it will continue to expand its talent pool to keep pace with corporate growth and meet product R&D demands. To this end, Xrazor Technology plans to engage multiple experts in drug development and in vitro diagnostics as technical advisors.

Hu Xiaofang, Partner at Yuanhe Origin Fund, stated, “For a long time, scientists, clinicians, and the biomedical industry have been constrained by inefficient, slow, and overly complex laboratory solutions. Xrazor Technology is building a disruptive automated laboratory platform designed to transform the output efficiency of healthcare and life sciences through integrated intelligent automation solutions. We believe this represents the future direction of laboratory development, and we look forward to collaborating with Xrazor Technology to help the company accelerate growth and rapidly commercialize new products.”

Li Rui, Partner at Shunwei Capital, stated, “The Shunwei team has long been bullish on the empowering potential of digitalization, intelligence, and automation in the healthcare and life sciences sectors, and has made strategic investments in sub-sectors such as surgical robots, AI-driven drug discovery, laboratory automation, and digital health. Currently, the life sciences industry is witnessing particularly strong demand for automation, ushering in a period of explosive growth as it transitions from labor-intensive operations to an industrialized stage. Therefore, amidst the rapid increase in automation penetration across the industry, Shunwei is highly optimistic about Xrazor’s potential as a premium product provider. With extensive experience in robotics R&D, we believe that under the leadership of its founding team, Xrazor will drive the automation process in the life sciences industry, liberating high-value intellectual productivity and time, and building the automated laboratories of the future.”

Mr. Yu Xiaoyong, Founding Managing Partner of Zhangke Lingyi, stated: “Congratulations to Xrazor Technology on completing this round of financing. Since its establishment in late 2020, under the leadership of Mr. He, Xrazor Technology has continuously refined its product direction, strengthened its management and technical teams, and basically formed a stable, efficient, and highly capable workforce, gradually gaining recognition within the industry. The successful completion of this financing round serves as a strong testament to this progress. Automation and intelligence represent major trends in the life sciences industry, with robotics and related technologies serving as key enablers for scenario implementation. The resulting products and technologies are productivity tools driving industry transformation. Originating in Zhangjiang, Xrazor Technology has leveraged the rich industrial and talent resources of the Greater Zhangjiang area to earn continuous recognition from leading customers. We remain bullish on this industry and on such a creative and execution-driven team, and we look forward to Xrazor Technology’s continued growth into an industry benchmark enterprise with support from all stakeholders.”

Yuanhe Origin, a member of Suzhou Yuanhe Holding Co., Ltd., is a market-oriented, specialized early-stage equity investment platform. It focuses primarily on investment opportunities in start-up and growth-stage enterprises within the Healthcare and TMT sectors. The platform manages ten funds with a total scale of approximately RMB 4 billion, comprising both VC funds and angel funds targeted at specific regions.

Yuanhe Origin’s investment style is characterized by a focus on early-stage ventures, a preference for technology-driven companies, and a steadfast commitment to its promises, earning it a strong reputation among early-stage tech startups. To date, it has invested in and managed over 200 high-quality enterprises, including Ascentage Pharma, CStone Pharmaceuticals, JW Therapeutics, Jiangsu Beiren, Tianzhun Technology, Biocell, and Zhizhu.

Shunwei Capital focuses on key sectors including mobile internet, Internet Plus, smart hardware, intelligent manufacturing, deep tech, consumer goods, enterprise services, and the electric vehicle ecosystem. Its representative portfolio companies in China and abroad include Xiaomi Corporation, Ninebot, Agora, iQIYI, NIO, ShareChat, Meesho, and over 400 other outstanding enterprises. By investing in visionary companies from the early to growth stages, Shunwei Capital aims to make our lives better.

Zhangke Lingyi is a local venture capital firm based in Zhangjiang, primarily investing in early- to mid-stage projects in the fields of biopharmaceuticals and innovative medical devices within Zhangjiang Science City. It has successively invested in companies such as ImmuneOnco, Nuomai Medical, Yinuo Pharmaceutical, Zhuowai Medical, Luoqi Biologics, Lingnuo Pharmaceuticals, Lingtai Biologics, and Xrazor Technology. The management team of Zhangke Lingyi has deep roots in Zhangjiang and possesses extensive industry, project, and information resources. By integrating various development elements essential for corporate growth—including capital, talent, development space, corporate collaborations, and policy information—the firm works alongside entrepreneurs to drive the rapid development of startups.